Stock FGEN FIBROGEN, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News FibroGen, Inc.

Equities

FGEN

US31572Q8087

Real-time Estimate Cboe BZX
Other stock markets
 11:41:43 2024-04-26 am EDT 		5-day change 1st Jan Change
1.01 USD -0.98% Intraday chart for FibroGen, Inc. -12.17% +13.96%
Apr. 15 Faron Pharmaceuticals reappoints former finance chief on interim basis AN
Apr. 03 Top Midday Decliners MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting
AQ
FibroGen, Inc. to Present Clinical Data from Dose Escalation Phase 1B Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer at 2024 American Society of Clinical Oncology Annual Meeting
CI
Faron Pharmaceuticals reappoints former finance chief on interim basis
AN
Top Midday Decliners
MT
FibroGen Says Phase 1 Study of Potential Prostate Cancer Treatment Shows Promise
MT
FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer
AQ
Fibrogen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer
CI
FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference
AQ
FibroGen : Corporate Presentation – March 2024
PU
Sector Update: Health Care Stocks Rise Late Afternoon
MT
Sector Update: Health Care Stocks Higher in Afternoon Trading
MT
FibroGen Shares Jump After CEO Stock Purchase
MT
FibroGen Names Deyaa Adib Chief Medical Officer
MT
FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer
AQ
FibroGen Appoints Deyaa Adib as Senior Vice President and Chief Medical Officer
CI
FibroGen : Corporate Presentation – March 2024
PU
FibroGen: Q4 Earnings Snapshot
AQ
Transcript : FibroGen, Inc., Q4 2023 Earnings Call, Feb 26, 2024
FibroGen regains rights to anemia drug from AstraZeneca
RE
FibroGen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. FGEN Stock
  4. News FibroGen, Inc.